Status:
UNKNOWN
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
Lead Sponsor:
Alexandria University
Collaborating Sponsors:
Science, Technology & Innovation Funding Authority (STIFA), Egypt
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.
Detailed Description
As the coronavirus disease (COVID-19) spreads worldwide, awaiting the development of a vaccine, researchers are looking among the arsenal of available drugs, for a potential cure or medication to impr...
Eligibility Criteria
Inclusion
- Patients with PCR positive for SARS-COV-2
- Hospitalized with moderate to severe respiratory symptoms as assessed by the Egyptian Ministry of Health National Guidelines
- Informed consent explained \& signed by patient or his 1st degree relatives or legally authorized representative.
Exclusion
- Pregnant women (or) breast feeding women
- Patients younger than 18 years of age
- Patients with known allergy to imatinib
- Total bilirubin, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) \> 5x upper limit of normal (ULN).
- Creatinine clearance (CrCl) \< 30 mL/minute.
- Patient already on mechanical ventilation at time of screening.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04422678
Start Date
June 1 2020
End Date
October 1 2020
Last Update
June 9 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.